Kristin Stephens - Feb 15, 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Development Officer
Signature
/s/ Gerald E. Quirk, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Feb 15, 2022
Transactions value $
$0
Form type
4
Date filed
2/17/2022, 03:08 PM
Previous filing
Jun 10, 2021
Next filing
Apr 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +100K $0.00 100K Feb 15, 2022 Common Stock 100K $1.59 Direct F1
transaction SYRS Restricted Stock Units Award $0 +80K $0.00 80K Feb 15, 2022 Common Stock 80K Direct F2, F3
transaction SYRS Restricted Stock Units Award $0 +200K $0.00 200K Feb 15, 2022 Common Stock 200K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3 These RSUs will vest in four equal annual installments commencing on March 31, 2023.
F4 These RSUs will vest in full on March 31, 2025.